PRA was awarded a rheumatoid arthritis study contract based on our strategy for achieving first-patient-in (FPI) by the end of the calendar year. PRA’s plan depended on a closely managed project with clear timelines and responsibilities, as well as selecting key sites that could support our goal. PRA reduced the project’s cost by approximately 15% through our ability to enroll the targeted number of patients with fewer sites and in a shorter time period.
Explore related content and topics
Blog
CRISPR Technology Offers New Hope for Patients with Devastating Diseases
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a powerful new gene-editing tool with unprecedented implications for the future…
Newsletter
Industry Watch
As we move into the final quarter of 2020, we bring you news of the discovery of a rare genetic form of dementia known as Vacuolar Tauopathy. From…
Blog
Ask the Experts: How Does Immunization Protect Us?
PRA experts from the Center for Vaccine Research—Darin Seehafer, Director of Therapeutic Expertise, and Lynlee Burton, Head, Center for Vaccine…